ANI Pharmaceuticals Inc (ANIP)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 100.00% | 62.71% | 56.13% | 53.45% | 58.19% |
| Operating profit margin | 0.10% | 9.65% | -7.92% | -15.04% | -7.71% |
| Pretax margin | -3.62% | 4.08% | -19.81% | -25.94% | -12.45% |
| Net profit margin | -3.01% | 3.86% | -15.14% | -19.71% | -10.82% |
The gross profit margin for ANI Pharmaceuticals Inc has shown a fluctuating trend over the years, starting at 58.19% in 2020, decreasing to 53.45% in 2021, and then increasing in subsequent years to 56.13% in 2022 and 62.71% in 2023 before reaching an exceptionally high 100% in 2024.
However, the operating profit margin paints a less favorable picture, with negative values in 2020 and 2021 (-7.71% and -15.04% respectively). The company then managed to improve its operating profit margin in 2023 to 9.65% but only slightly positive at 0.10% in 2024.
Similarly, the pretax margin was negative from 2020 to 2022 (-12.45%, -25.94%, and -19.81% consecutively) before turning positive at 4.08% in 2023, only to dip back to -3.62% in 2024.
The net profit margin also tells a story of losses in the initial years, with -10.82% in 2020 and -19.71% in 2021. The company managed to achieve a positive net profit margin of 3.86% in 2023, but it fell back to -3.01% in 2024.
These ratios indicate that ANI Pharmaceuticals Inc has faced profitability challenges, particularly in the earlier years but managed to show signs of improvement in the later years, with some ratios turning positive. However, the consistent negative operating and net profit margins suggest that the company may still be grappling with operational efficiency and cost management issues that need attention for sustained profitability.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 0.05% | 5.19% | -3.30% | -4.21% | -3.48% |
| Return on assets (ROA) | -1.44% | 2.08% | -6.30% | -5.52% | -4.89% |
| Return on total capital | -1.08% | 10.23% | -2.63% | -13.64% | -7.96% |
| Return on equity (ROE) | -4.32% | 4.10% | -14.15% | -11.88% | -11.52% |
ANI Pharmaceuticals Inc's profitability ratios show fluctuating performance over the five-year period analyzed.
- Operating return on assets (Operating ROA) improved from negative figures in 2020 and 2021 to a positive 5.19% in 2023, indicating the company's ability to generate profits from its operations relative to its total assets. However, the ratio declined slightly to 0.05% in 2024.
- Return on assets (ROA) also saw a similar trend, with negative values in the first three years, a positive turn in 2023 at 2.08%, followed by a negative ROA of -1.44% in 2024. ROA measures the company's efficiency in generating profits from its assets.
- Return on total capital experienced significant fluctuations, ranging from -13.64% in 2021 to a high of 10.23% in 2023, reflecting the return the company generates from both debt and equity capital employed. However, the ratio dropped to -1.08% in 2024.
- Return on equity (ROE) showed a similar pattern to the other ratios, with negative values in the first three years followed by a positive ROE of 4.10% in 2023, before declining to -4.32% in 2024. ROE measures the return the company generates for its shareholders' equity.
Overall, ANI Pharmaceuticals Inc's profitability ratios indicate a mixed performance, with improvements in certain years but inconsistent profitability levels across the different measures. Further analysis of the company's operational and financial strategies may be needed to understand the factors driving these fluctuations in profitability.